The importance of the eicosanoid pathway in lung cancer.
Non-steroidal anti-inflammatory agents (NSAIDs) inhibit the conversion of arachadonic acid to a class of inflammatory mediators known as eicosanoids. These minimally toxic drugs have demonstrated important anti-cancer properties in colorectal cancer and pre-clinical models have shown their potential for use in the treatment of non-small cell lung cancer (NSCLC). Clinical trials are underway investigating the efficacy of eicosanoid inhibitors alone and in combination with radiation and chemotherapy.